Longboard Pharmaceuticals, Inc. Common Stock
LBPH US54300N1037 inactive
Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. The company is working to improve a portfolio of centrally acting product candidates designed to be selective for specific G protein-coupled receptors (GPCRs). The company is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -71% | -33% | 24% | 138% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Kaye Randall CMO |
59.04 USD |
16,667 Sold |
983,936 USD |
15/10/2024 | 15/10/2024 |
| Kaye Randall CMO |
30.89 USD |
9,366 Sold |
289,278 USD |
16/09/2024 | 16/09/2024 |
| Kaye Randall CMO |
31.81 USD |
4,200 Sold |
133,622 USD |
16/09/2024 | 16/09/2024 |
| Kaye Randall CMO |
33.12 USD |
1,200 Sold |
39,750 USD |
16/09/2024 | 16/09/2024 |
| Kaye Randall CMO |
34.04 USD |
1,900 Sold |
64,668 USD |
16/09/2024 | 16/09/2024 |
| Kaye Randall CMO |
34.55 USD |
10,476 Sold |
361,948 USD |
23/01/2024 | 12/08/2024 |
| Kaye Randall CMO |
35.03 USD |
6,191 Sold |
216,856 USD |
23/01/2024 | 12/08/2024 |
| Kaye Randall CMO |
20.87 USD |
100 Sold |
2,087 USD |
23/01/2024 | 25/06/2024 |
| Arena Pharmaceuticals Inc |
24.25 USD |
3,978,540 Sold |
96,479,595 USD |
25/01/2024 | 25/01/2024 |
| Kaye Randall CMO |
24.82 USD |
100 Bought |
2,482 USD |
23/01/2024 | 23/01/2024 |